Mammalian Prion Biology: One Century of Evolving Concepts

Cell

Volumn 116, Issue 2, 2004, Pages 313-327

  Aguzzi, Adriano ^a   Polymenidou, Magdalini ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTHRACYCLINE DERIVATIVE; CONGO RED; CURCUMIN; POLYAMINE DERIVATIVE; POLYANION; PORPHYRIN DERIVATIVE; PRION PROTEIN;

BIOASSAY; BOVINE SPONGIFORM ENCEPHALOPATHY; CODON; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; DRUG EFFICACY; HISTORY OF MEDICINE; HUMAN; IATROGENIC DISEASE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KURU; MAMMAL; MOLECULAR BIOLOGY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PHENOTYPE; POPULATION RESEARCH; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SCRAPIE; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; WESTERN BLOTTING; YEAST;

BOVINAE; MAMMALIA;

EID: 0842281643     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(03)01031-6     Document Type: Review

References (160)

1. Aguzzi A. Between cows and monkeys. Nature. 381:1996;734.
2. Aguzzi A., Weissmann C. Spongiform encephalopathies. a suspicious signature Nature. 383:1996;666-667.
3. Aguzzi A., Weissmann C. Prion research. the next frontiers Nature. 389:1997;795-798.
4. Aguzzi A., Haass C. Games played by rogue proteins in prion and Alzheimer's disease. Science. 302:2003;814-818.
5. Aguzzi A., Hardt W.D. Dangerous liaisons between a microbe and the prion protein. J. Exp. Med. 198:2003;1-4.
6. Alper T., Cramp W.A., Haig D.A., Clarke M.C. Does the agent of scrapie replicate without nucleic acid? Nature. 214:1967;764-766.
7. Alper T., Haig D.A., Clarke M.C. The exceptionally small size of the scrapie agent. Biochem. Biophys. Res. Commun. 22:1966;278-284.
8. Andrews N.J., Farrington C.P., Ward H.J., Cousens S.N., Smith P.G., Molesworth A.M., Knight R.S., Ironside J.W., Will R.G. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet. 361:2003;751-752.
9. Basler K., Oesch B., Scott M., Westaway D., Walchli M., Groth D.F., McKinley M.P., Prusiner S.B., Weissmann C. Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell. 46:1986;417-428.
10. Behrens A., Aguzzi A. Small is not beautiful. antagonizing functions for the prion protein PrP(C) and its homologue Dpl Trends Neurosci. 25:2002;150-154.
11. Bellon A., Seyfert-Brandt W., Lang W., Baron H., Groner A., Vey M. Improved conformation-dependent immunoassay. suitability for human prion detection with enhanced sensitivity J. Gen. Virol. 84:2003;1921-1925.
12. Bessen R.A., Kocisko D.A., Raymond G.J., Nandan S., Lansbury P.T., Caughey B. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature. 375:1995;698-700.
13. Blättler T., Brandner S., Raeber A.J., Klein M.A., Voigtländer T., Weissmann C., Aguzzi A. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature. 389:1997;69-73.
14. Bolton D.C., McKinley M.P., Prusiner S.B. Identification of a protein that purifies with the scrapie prion. Science. 218:1982;1309-1311.
15. Bosque P.J., Prusiner S.B. Cultured cell sublines highly susceptible to prion infection. J. Virol. 74:2000;4377-4386.
16. Brandner S., Isenmann S., Raeber A., Fischer M., Sailer A., Kobayashi Y., Marino S., Weissmann C., Aguzzi A. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature. 379:1996;339-343. a.
17. Brandner S., Raeber A., Sailer A., Blattler T., Fischer M., Weissmann C., Aguzzi A. Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system. Proc. Natl. Acad. Sci. USA. 93:1996;13148-13151. b.
18. Brown D.R., Schulz-Schaeffer W.J., Schmidt B., Kretzschmar H.A. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp. Neurol. 146:1997;104-112.
19. Brown D.R., Wong B.S., Hafiz F., Clive C., Haswell S.J., Jones I.M. Normal prion protein has an activity like that of superoxide dismutase. Biochem. J. 344:1999;1-5.
20. Bruce M.E., Will R.G., Ironside J.W., McConnell I., Drummond D., Suttie A., McCardle L., Chree A., Hope J., Birkett C.et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 389:1997;498-501.
21. Büeler H.R., Fischer M., Lang Y., Bluethmann H., Lipp H.P., DeArmond S.J., Prusiner S.B., Aguet M., Weissmann C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 356:1992;577-582.
22. Büeler H.R., Aguzzi A., Sailer A., Greiner R.A., Autenried P., Aguet M., Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell. 73:1993;1339-1347.
23. Cashman N.R., Loertscher R., Nalbantoglu J., Shaw I., Kascsak R.J., Bolton D.C., Bendheim P.E. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell. 61:1990;185-192.
24. Caughey B., Race R.E. Potent inhibition of scrapie-associated PrP accumulation by congo red. J. Neurochem. 59:1992;768-771.
25. Caughey B., Raymond G.J. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol. 67:1993;643-650.
26. Caughey B., Raymond L.D., Raymond G.J., Maxson L., Silveira J., Baron G.S. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol. 77:2003;5499-5502.
27. Caughey B.W., Dong A., Bhat K.S., Ernst D., Hayes S.F., Caughey W.S. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry. 30:1991;7672-7680.
28. Chandler R.L. Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet. 1:1961;1378-1379.
29. Chesebro B. BSE and prions. uncertainties about the agent Science. 279:1998;42-43.
30. Chesebro B., Race R., Wehrly K., Nishio J., Bloom M., Lechner D., Bergstrom S., Robbins K., Mayer L., Keith J.M. Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature. 315:1985;331-333.
31. Collinge J., Whittington M.A., Sidle K.C., Smith C.J., Palmer M.S., Clarke A.R., Jefferys J.G. Prion protein is necessary for normal synaptic function. Nature. 370:1994;295-297.
32. Collinge J., Sidle K.C., Meads J., Ironside J., Hill A.F. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature. 383:1996;685-690.
33. Collins S.J., Lewis V., Brazier M., Hill A.F., Fletcher A., Masters C.L. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. 52:2002;503-506.
34. Cooper E. Quinacrine in possible or probable CJD. it is blinded investigators, not patients, who must be in equipoise over treatment BMJ. 324:2002;239.
35. Creutzfeldt H.G. Über eine eigenartige herdförmige Erkrankung des Zentralnervensystems. Z ges Neurol Psychiatr. 57:1920;1-19.
36. Cuille J., Chelle P.L. Experimental transmission of trembling to the goat. Comptes Rendus des Seances de l'Academie des Sciences. 208:1939;1058-1160.
37. DeArmond S.J., Prusiner S.B. Etiology and pathogenesis of prion diseases. Am. J. Pathol. 146:1995;785-811.
38. Dickinson A.G., Meikle V.M., Fraser H. Identification of a gene which controls the incubation period of some strains of scrapie agent in mice. J. Comp. Pathol. 78:1968;293-299.
39. Drisaldi B., Stewart R.S., Adles C., Stewart L.R., Quaglio E., Biasini E., Fioriti L., Chiesa R., Harris D.A. Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. J. Biol. Chem. 278:2003;21732-21743.
40. Duffy P., Wolf J., Collins G., DeVoe A.G., Streeten B., Cowen D. Possible person-to-person transmission of Creutzfeldt-Jakob disease. N. Engl. J. Med. 290:1974;692-693.
41. Enari M., Flechsig E., Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. USA. 98:2001;9295-9299.
42. Fischer M.B., Roeckl C., Parizek P., Schwarz H.P., Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature. 408:2000;479-483.
43. Frigg R., Klein M.A., Hegyi I., Zinkernagel R.M., Aguzzi A. Scrapie pathogenesis in subclinically infected B-cell-deficient mice. J. Virol. 73:1999;9584-9588.
44. Gabizon R., McKinley M.P., Groth D., Prusiner S.B. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc. Natl. Acad. Sci. USA. 85:1988;6617-6621.
45. Gajdusek D.C., Zigas V. Degenerative disease of the central nervous system in New Guinea - the endemic occurrence of 'kuru' in the native population. N. Engl. J. Med. 257:1957;974-978.
46. Gajdusek D.C., Gibbs C.J., Alpers M. Experimental transmission of a Kuru-like syndrome to chimpanzees. Nature. 209:1966;794-796.
47. Gajdusek D.C., Gibbs C.J. Jr., Alpers M. Transmission and passage of experimenal "kuru" to chimpanzees. Science. 155:1967;212-214.
48. Gibbs C.J. Jr., Gajdusek D.C., Asher D.M., Alpers M.P., Beck E., Daniel P.M., Matthews W.B. Creutzfeldt-Jakob disease (spongiform encephalopathy). transmission to the chimpanzee Science. 161:1968;388-389.
49. Glatzel M., Heppner F.L., Albers K.M., Aguzzi A. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron. 31:2001;25-34.
50. Glatzel M., Abela E., Maissen M., Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 349:2003;1812-1820. a.
51. Glatzel M., Ott P.M., Lindner T., Gebbers J.O., Gmur A., Wuest W., Huber G., Moch H., Podvinec M., Stamm B., Aguzzi A. Human prion diseases. epidemiology and integrated risk assessment Lancet Neurol. 2:2003;757-763. b.
52. Glatzel M., Rogivue C., Ghani A., Streffer J.R., Amsler L., Aguzzi A. Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet. 360:2002;139-141.
53. Glockshuber R., Hornemann S., Billeter M., Riek R., Wider G., Wuthrich K. Prion protein structural features indicate possible relations to signal peptidases. FEBS Lett. 426:1998;291-296.
54. Gorodinsky A., Harris D.A. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J. Cell Biol. 129:1995;619-627.
55. Griffith J.S. Self-replication and scrapie. Nature. 215:1967;1043-1044.
56. Hadlow W.J. Scrapie and kuru. Lancet. 2:1959;289-290.
57. Harmey J.H., Doyle D., Brown V., Rogers M.S. The cellular isoform of the prion protein, PrPc, is associated with caveolae in mouse neuroblastoma (N2a) cells. Biochem. Biophys. Res. Commun. 210:1995;753-759.
58. Hegde R.S., Mastrianni J.A., Scott M.R., DeFea K.A., Tremblay P., Torchia M., DeArmond S.J., Prusiner S.B., Lingappa V.R. A transmembrane form of the prion protein in neurodegenerative disease. Science. 279:1998;827-834.
59. Hegde R.S., Tremblay P., Groth D., DeArmond S.J., Prusiner S.B., Lingappa V.R. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature. 402:1999;822-826.
60. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., Zinkernagel R., Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10:2004;187-192.
61. Heppner F.L., Musahl C., Arrighi I., Klein M.A., Rulicke T., Oesch B., Zinkernagel R.M., Kalinke U., Aguzzi A. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 294:2001;178-182.
62. Hill A.F., Butterworth R.J., Joiner S., Jackson G., Rossor M.N., Thomas D.J., Frosh A., Tolley N., Bell J.E., Spencer M.et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet. 353:1999;183-189.
63. Hill A.F., Desbruslais M., Joiner S., Sidle K.C., Gowland I., Collinge J., Doey L.J., Lantos P. The same prion strain causes vCJD and BSE. Nature. 389:1997;448-450. a [letter].
64. Hill A.F., Zeidler M., Ironside J., Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet. 349:1997;99. b.
65. Hilton D.A., Fathers E., Edwards P., Ironside J.W., Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet. 352:1998;703-704.
66. Horiuchi M., Caughey B. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J. 18:1999;3193-3203.
67. Horiuchi M., Priola S.A., Chabry J., Caughey B. Interactions between heterologous forms of prion protein. binding, inhibition of conversion, and species barriers Proc. Natl. Acad. Sci. USA. 97:2000;5836-5841.
68. Houston F., Foster J.D., Chong A., Hunter N., Bostock C.J. Transmission of BSE by blood transfusion in sheep. Lancet. 356:2000;999-1000.
69. Hsiao K., Baker H.F., Crow T.J., Poulter M., Owen F., Terwilliger J.D., Westaway D., Ott J., Prusiner S.B. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature. 338:1989;342-345.
70. Hutter G., Heppner F.L., Aguzzi A. No superoxide dismutase activity of cellular prion protein in vivo. Biol. Chem. 384:2003;1279-1285.
71. Jackson G.S., Hosszu L.L., Power A., Hill A.F., Kenney J., Saibil H., Craven C.J., Waltho J.P., Clarke A.R., Collinge J. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science. 283:1999;1935-1937.
72. Jakob A. Über eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswertem anatomischem Befunde. (Spastische Pseudosklerose- Encephalomyelopathie mit disseminierten Degenerationsherden). Z ges Neurol Psychiatr. 64:1921;147-228.
73. Jarrett J.T., Lansbury P.T. Jr. Seeding "one-dimensional crystallization" of amyloid. a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 73:1993;1055-1058.
74. Kitamoto T., Muramoto T., Mohri S., Doh ura K., Tateishi J. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. J. Virol. 65:1991;6292-6295.
75. Klein M.A., Frigg R., Flechsig E., Raeber A.J., Kalinke U., Bluethmann H., Bootz F., Suter M., Zinkernagel R.M., Aguzzi A. A crucial role for B cells in neuroinvasive scrapie. Nature. 390:1997;687-690.
76. Klein M.A., Frigg R., Raeber A.J., Flechsig E., Hegyi I., Zinkernagel R.M., Weissmann C., Aguzzi A. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat. Med. 4:1998;1429-1433.
77. Klein M.A., Kaeser P.S., Schwarz P., Weyd H., Xenarios I., Zinkernagel R.M., Carroll M.C., Verbeek J.S., Botto M., Walport M.J.et al. Complement facilitates early prion pathogenesis. Nat. Med. 7:2001;488-492.
78. Klohn P.C., Stoltze L., Flechsig E., Enari M., Weissmann C. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc. Natl. Acad. Sci. USA. 100:2003;11666-11671.
79. Knaus K.J., Morillas M., Swietnicki W., Malone M., Surewicz W.K., Yee V.C. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat. Struct. Biol. 8:2001;770-774.
80. Kocisko D.A., Come J.H., Priola S.A., Chesebro B., Raymond G.J., Lansbury P.T., Caughey B. Cell-free formation of protease-resistant prion protein. Nature. 370:1994;471-474.
81. Korth C., Stierli B., Streit P., Moser M., Schaller O., Fischer R., Schulz-Schaeffer W., Kretzschmar H., Raeber A., Braun U.et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature. 390:1997;74-77.
82. Korth C., May B.C., Cohen F.E., Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA. 98:2001;9836-9841.
83. Kurschner C., Morgan J.I., Yehiely F., Bamborough P., Da Costa M., Perry B.J., Thinakaran G., Cohen F.E., Carlson G.A., Prusiner S.B. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system. identification of candidate proteins binding to prion protein Brain Res. Mol. Brain Res. 30:1995;165-168.
84. Lacroute F. Non-Mendelian mutation allowing ureidosuccinic acid uptake in yeast. J. Bacteriol. 106:1971;519-522.
85. Li L., Lindquist S. Creating a protein-based element of inheritance. Science. 287:2000;661-664.
86. Luhrs T., Riek R., Guntert P., Wuthrich K. NMR structure of the human doppel protein. J. Mol. Biol. 326:2003;1549-1557.
87. Ma J., Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science. 298:2002;1785-1788.
88. Ma J., Wollmann R., Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science. 298:2002;1781-1785.
89. Mabbott N.A., Bruce M.E., Botto M., Walport M.J., Pepys M.B. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat. Med. 7:2001;485-487.
90. Mallucci G.R., Ratte S., Asante E.A., Linehan J., Gowland I., Jefferys J.G., Collinge J. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J. 21:2002;202-210.
91. Mallucci G., Dickinson A., Linehan J., Klohn P.C., Brandner S., Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 302:2003;871-874.
92. Manson J.C., Clarke A.R., Hooper M.L., Aitchison L., McConnell I., Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol. Neurobiol. 8:1994;121-127.
93. McKinley M.P., Bolton D.C., Prusiner S.B. A protease-resistant protein is a structural component of the scrapie prion. Cell. 35:1983;57-62.
94. Mead S., Stumpf M.P., Whitfield J., Beck J.A., Poulter M., Campbell T., Uphill J.B., Goldstein D., Alpers M., Fisher E.M., Collinge J. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science. 300:2003;640-643.
95. Meier P., Genoud N., Prinz M., Maissen M., Rulicke T., Zurbriggen A., Raeber A.J., Aguzzi A. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell. 113:2003;49-60.
96. Montrasio F., Frigg R., Glatzel M., Klein M.A., Mackay F., Aguzzi A., Weissmann C. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science. 288:2000;1257-1259.
97. Moore R.C., Hope J., McBride P.A., McConnell I., Selfridge J., Melton D.W., Manson J.C. Mice with gene targetted prion protein alterations show that Prnp, Sinc and Prni are congruent. Nat. Genet. 18:1998;118-125.
98. Moore R.C., Lee I.Y., Silverman G.L., Harrison P.M., Strome R., Heinrich C., Karunaratne A., Pasternak S.H., Chishti M.A., Liang Y.et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J. Mol. Biol. 292:1999;797-817.
99. Mouillet-Richard S., Ermonval M., Chebassier C., Laplanche J.L., Lehmann S., Launay J.M., Kellermann O. Signal transduction through prion protein. Science. 289:2000;1925-1928.
100. Naslavsky N., Stein R., Yanai A., Friedlander G., Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J. Biol. Chem. 272:1997;6324-6331.
101. Oesch B., Westaway D., Walchli M., McKinley M.P., Kent S.B., Aebersold R., Barry R.A., Tempst P., Teplow D.B., Hood L.E., Weissmann C. A cellular gene encodes scrapie PrP 27-30 protein. Cell. 40:1985;735-746.
102. Oesch B., Teplow D.B., Stahl N., Serban D., Hood L.E., Prusiner S.B. Identification of cellular proteins binding to the scrapie prion protein. Biochemistry. 29:1990;5848-5855.
103. Pan K.M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R.J., Cohen F.E.et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA. 90:1993;10962-10966.
104. Paramithiotis E., Pinard M., Lawton T., LaBoissiere S., Leathers V.L., Zou W.Q., Estey L.A., Lamontagne J., Lehto M.T., Kondejewski L.H.et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. 9:2003;893-899.
105. Pattison I.H., Millson G.C. Scrapie produced experimentally in goats with special reference to the clinical syndrome. J. Comp. Pathol. 71:1961;101-108.
106. Peretz D., Williamson R.A., Kaneko K., Vergara J., Leclerc E., Schmitt-Ulms G., Mehlhorn I.R., Legname G., Wormald M.R., Rudd P.M.et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature. 412:2001;739-743.
107. Perrier V., Kaneko K., Safar J., Vergara J., Tremblay P., DeArmond S.J., Cohen F.E., Prusiner S.B., Wallace A.C. Dominant-negative inhibition of prion replication in transgenic mice. Proc. Natl. Acad. Sci. USA. 99:2002;13079-13084.
108. Popper K. Selections from the logic of scientific discovery. Boyd R., Gasper P., Trout J.D. The Philosophy of Science. 1991;100-119 The MIT Press, Cambridge, MA.
109. Prinz M., Heikenwalder M., Junt T., Schwarz P., Glatzel M., Heppner F.L., Fu Y.X., Lipp M., Aguzzi A. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature. 425:2003;957-962. a Published online October 15, 2003. doi: 10.1038/nature02072.
110. Prinz M., Heikenwalder M., Schwarz P., Takeda K., Akira S., Aguzzi A. Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep. 4:2003;195-199. b.
111. Prinz M., Huber G., Macpherson A.J., Heppner F.L., Glatzel M., Eugster H.P., Wagner N., Aguzzi A. Oral prion infection requires normal numbers of peyer's patches but not of enteric lymphocytes. Am. J. Pathol. 162:2003;1103-1111. c.
112. Priola S.A., Raines A., Caughey W.S. Porphyrin and phthalocyanine antiscrapie compounds. Science. 287:2000;1503-1506.
113. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science. 216:1982;136-144.
114. Prusiner S.B., Hadlow W.J., Eklund C.M., Race R.E. Sedimentation properties of the scrapie agent. Proc. Natl. Acad. Sci. USA. 74:1977;4656-4660.
115. Prusiner S.B., Groth D.F., Cochran S.P., Masiarz F.R., McKinley M.P., Martinez H.M. Molecular properties, partial purification, and assay by incubation period measurements of the hamster scrapie agent. Biochemistry. 19:1980;4883-4891.
116. Prusiner S.B., Groth D.F., McKinley M.P., Cochran S.P., Bowman K.A., Kasper K.C. Thiocyanate and hydroxyl ions inactivate the scrapie agent. Proc. Natl. Acad. Sci. USA. 78:1981;4606-4610.
117. Prusiner S.B., Groth D., Serban A., Koehler R., Foster D., Torchia M., Burton D., Yang S.L., DeArmond S.J. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl. Acad. Sci. USA. 90:1993;10608-10612.
118. Race R.E., Fadness L.H., Chesebro B. Characterization of scrapie infection in mouse neuroblastoma cells. J. Gen. Virol. 68:1987;1391-1399.
119. Revesz T., Holton J.L., Lashley T., Plant G., Rostagno A., Ghiso J., Frangione B. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 12:2002;343-357.
120. Rieger R., Edenhofer F., Lasmezas C.I., Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat. Med. 3:1997;1383-1388.
121. Riek R., Hornemann S., Wider G., Billeter M., Glockshuber R., Wuthrich K. Nmr structure of the mouse prion protein domain Prp(121-231). Nature. 382:1996;180-182.
122. Riek R., Hornemann S., Wider G., Glockshuber R., Wüthrich K. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett. 413:1997;282-288.
123. Rossi D., Cozzio A., Flechsig E., Klein M.A., Aguzzi A., Weissmann C. Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. EMBO J. 20:2001;1-9.
124. Roucou X., Guo Q., Zhang Y., Goodyer C.G., LeBlanc A.C. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J. Biol. Chem. 278:2003;40877-40881.
125. Saborio G.P., Permanne B., Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 411:2001;810-813.
126. Safar J., Wille H., Itri V., Groth D., Serban H., Torchia M., Cohen F.E., Prusiner S.B. Eight prion strains have PrP(Sc) molecules with different conformations. Nat. Med. 4:1998;1157-1165.
127. Safar J.G., Scott M., Monaghan J., Deering C., Didorenko S., Vergara J., Ball H., Legname G., Leclerc E., Solforosi L.et al. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat. Biotechnol. 20:2002;1147-1150.
128. Sailer A., Büeler H., Fischer M., Aguzzi A., Weissmann C. No propagation of prions in mice devoid of PrP. Cell. 77:1994;967-968.
129. Sakaguchi S., Katamine S., Nishida N., Moriuchi R., Shigematsu K., Sugimoto T., Nakatani A., Kataoka Y., Houtani T., Shirabe S.et al. Loss of cerebellar purkinje cells in aged mice homozygous for a disrupted Prp gene. Nature. 380:1996;528-531.
130. Sakudo A., Lee D.C., Saeki K., Nakamura Y., Inoue K., Matsumoto Y., Itohara S., Onodera T. Impairment of superoxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line. Biochem. Biophys. Res. Commun. 308:2003;660-667.
131. Schmitt-Ulms G., Legname G., Baldwin M.A., Ball H.L., Bradon N., Bosque P.J., Crossin K.L., Edelman G.M., DeArmond S.J., Cohen F.E., Prusiner S.B. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J. Mol. Biol. 314:2001;1209-1225.
132. Schreuder B.E.C., Vankeulen L.J.M., Vromans M.E.W., Langeveld J.P.M., Smits M.A. Preclinical test for prion diseases. Nature. 381:1996;563.
133. Schwartz, M. (2003). How the cows turned mad (University of California Press).
134. Scoazec J.Y., Krolak-Salmon P., Casez O., Besson G., Thobois S., Kopp N., Perret-Liaudet A., Streichenberger N. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 53:2003;546-547.
135. Scott M., Foster D., Mirenda C., Serban D., Coufal F., Waelchli M., Torchia M., Groth D., Carlson G., DeArmond S.J.et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell. 59:1989;847-857.
136. Sethi S., Lipford G., Wagner H., Kretzschmar H. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet. 360:2002;229-230.
137. Shmerling D., Hegyi I., Fischer M., Blattler T., Brandner S., Gotz J., Rulicke T., Flechsig E., Cozzio A., von Mering C.et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell. 93:1998;203-214.
138. Soto C., Kascsak R.J., Saborio G.P., Aucouturier P., Wisniewski T., Prelli F., Kascsak R., Mendez E., Harris D.A., Ironside J.et al. Reversion of prion protein conformational changes by synthetic beta- sheet breaker peptides. Lancet. 355:2000;192-197.
139. Souan L., Tal Y., Felling Y., Cohen I.R., Taraboulos A., Mor F. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. Immunol. 31:2001;2338-2346.
140. Supattapone S., Wille H., Uyechi L., Safar J., Tremblay P., Szoka F.C., Cohen F.E., Prusiner S.B., Scott M.R. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol. 75:2001;3453-3461.
141. Tagliavini F., McArthur R.A., Canciani B., Giaccone G., Porro M., Bugiani M., Lievens P.M., Bugiani O., Peri E., Dall'Ara P.et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science. 276:1997;1119-1122.
142. Tobler I., Gaus S.E., Deboer T., Achermann P., Fischer M., Rülicke T., Moser M., Oesch B., McBride P.A., Manson J.C. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature. 380:1996;639-642.
143. True H.L., Lindquist S.L. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature. 407:2000;477-483.
144. Valleron A.J., Boelle P.Y., Will R., Cesbron J.Y. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science. 294:2001;1726-1728.
145. Wadsworth J.D.F., Joiner S., Hill A.F., Campbell T.A., Desbruslais M., Luthert P.J., Collinge J. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-blotting assay. Lancet. 358:2001;171-180.
146. Waggoner D.J., Drisaldi B., Bartnikas T.B., Casareno R.L., Prohaska J.R., Gitlin J.D., Harris D.A. Brain copper content and cuproenzyme activity do not vary with prion protein Expression level. J. Biol. Chem. 275:2000;7455-7458.
147. Watarai M., Kim S., Erdenebaatar J., Makino S., Horiuchi M., Shirahata T., Sakaguchi S., Katamine S. Cellular prion protein promotes Brucella infection into macrophages. J. Exp. Med. 198:2003;5-17.
148. Weissmann C. Spongiform encephalopathies. The prion's progress. Nature. 349:1991;569-571.
149. Weissmann C., Aguzzi A. Perspectives. neurobiology. PrP's double causes trouble Science. 286:1999;914-915.
150. Wells G.A., Scott A.C., Johnson C.T., Gunning R.F., Hancock R.D., Jeffrey M., Dawson M., Bradley R. A novel progressive spongiform encephalopathy in cattle. Vet. Rec. 121:1987;419-420.
151. Westaway D., Goodman P.A., Mirenda C.A., McKinley M.P., Carlson G.A., Prusiner S.B. Distinct prion proteins in short and long scrapie incubation period mice. Cell. 51:1987;651-662.
152. White A.R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J., Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 422:2003;80-83.
153. Wickner R.B. as an altered URE2 protein. evidence for a prion analog in Saccharomyces cerevisiae Science. 264:1994;566-569. [URE3].
154. Will R.G., Ironside J.W., Zeidler M., Cousens S.N., Estibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A., Smith P.G. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 347:1996;921-925.
155. Wille H., Michelitsch M.D., Guenebaut V., Supattapone S., Serban A., Cohen F.E., Agard D.A., Prusiner S.B. Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl. Acad. Sci. USA. 99:2002;3563-3568.
156. Williams E.S., Young S. Chronic wasting disease of captive mule deer. a spongiform encephalopathy J. Wildl. Dis. 16:1980;89-98.
157. Yehiely, F., Bamborough, P., Costa, M.D., Perry, B.J., Thinakaran, G., Cohen, F.E., Carlson, G.A., and Prusiner, S.B. (2002). Identification of Candidate Proteins Binding to Prion Protein. Volume 3, Number 4 (1997), pages 339-355. Neurobiol. Dis. 10, 67-68.
158. Zanata S.M., Lopes M.H., Mercadante A.F., Hajj G.N., Chiarini L.B., Nomizo R., Freitas A.R., Cabral A.L., Lee K.S., Juliano M.A.et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. EMBO J. 21:2002;3307-3316.
159. Zanusso G., Ferrari S., Cardone F., Zampieri P., Gelati M., Fiorini M., Farinazzo A., Gardiman M., Cavallaro T., Bentivoglio M.et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N. Engl. J. Med. 348:2003;711-719.
160. Zijlstra M., Bix M., Simister N.E., Loring J.M., Raulet D.H., Jaenisch R. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature. 344:1990;742-746.